Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fat-Derived stem cells injected into spine to fight progressive MS

NCT ID NCT06592703

Disease control Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether repeated injections of stem cells from donated fat tissue are safe for people with primary progressive multiple sclerosis (MS). Ten participants will receive the cells directly into the spinal canal. The main goal is to check for serious side effects, but researchers will also watch for any signs that the treatment might slow disability progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
donor fat-derived stem cells (mesenchymal stromal cells)
What this could lead to
If safe and effective, this could point toward a new way to slow or stop worsening disability in primary progressive multiple sclerosis.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not proof of benefit. The treatment may not work, and there are risks from the injections and the cells themselves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with Primary Progressive MS according to the criteria of Mc Donald 2017 (Thompson et al Lancet neurol, 2017) * Age between 18 and 55 years * EDSS score: 3 to 6 at inclusion * Documented evidence of disability progression independent of relapse activity at any point in time over the 2 years prior to the screening visit * Positive CSF with oligoclonal bands * For women of childbearing potential (WOCBP), effective contraception as per the CFTG recommendations (version 1.1) * Having signed a free, informed and written consent * Affiliated to social security scheme Exclusion Criteria: * Inflammatory activity during the past year (relapses or new T2 MRI lesions) * Disease Modifying Drugs during the past year * Treatment with high dose corticosteroids during the 30 days preceding the inclusion * Contra indication to lumbar puncture/intrathecal infusion: intracranial hypertension, puncture site infections, severe thrombocytopenia (\<50 G/L), anticoagulant or fibrinolytic treatment * Participation in another therapeutic trial in the last 6 months * Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty, pregnant or breastfeeding women, minors, persons unable to express their consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis primary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP Henri Mondor

    ACTIVE_NOT_RECRUITING

    Créteil, France

  • CHU Rennes

    RECRUITING

    Rennes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.